Max Robotics — Global Service Robot Directory + US Certification

About

JM Carvajal is a prominent gynecologic oncologist whose work has significantly advanced the surgical management of cervical cancer. Her research centers on optimizing treatment for early-stage disease, with a particular focus on fertility-sparing and conservative surgical approaches. Carvajal’s most impactful contribution is the landmark "23 Concerv" prospective trial (2019), which evaluated conservative surgery for low-risk early-stage cervical cancer. This study, cited 15 times, provided critical evidence supporting less radical procedures, thereby reducing morbidity while maintaining oncologic safety—a paradigm shift that has influenced clinical guidelines and patient counseling. Her work addresses the delicate balance between cancer control and quality of life, especially for younger patients. Carvajal’s achievements include leading multi-institutional collaborations and contributing to the development of risk-stratified treatment protocols. Her research has been instrumental in challenging traditional radical hysterectomy standards, offering women with low-risk disease less invasive options. Through her rigorous clinical trials and translational insights, Carvajal continues to shape the future of gynecologic oncology, making her a key figure in the movement toward personalized, less morbid cancer care.